UnknownNCT03337568

Allogeneic HCT Using Uniform Conditioning Regimen Regardless of Donors (MS, MU, or HF) for AML in Remission

Studying Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Asan Medical Center
Principal Investigator
Kyoo-Hyung Lee, MD
University of Ulsan, Asan Medical Center
Intervention
allogeneic hematopoietic cell transplantation(procedure)
Enrollment
110 enrolled
Eligibility
16-75 years · All sexes
Timeline
20172021

Study locations (1)

Collaborators

Korea Research Institute of Bioscience & Biotechnology

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03337568 on ClinicalTrials.gov

Other trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Additional recruiting or active studies for the same condition.

See all trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

← Back to all trials